E2F5 and glioblastoma: After IDH mutant patients were excluded from both groups of GBM, E2F3 decreased significantly (p < 0.05) in recurrent patients, and E2F5 decreased significantly in secondary GBM IDH wild-type patients compared with primary GBM patients.